References
- US Food and Drug AdministrationGuidance for industry – drug interaction studies: study design, data analysis, implications for dosing, and labeling recommendations2012 Available from: https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdfAccessed March 16, 2017
- HarrisonAGardnerIHayTCase studies addressing human pharmacokinetic uncertainty using a combination of pharmacokinetic simulation and alternative first in human paradigmsXenobiotica2012421 57 7421992032
- MaedaKSugiyamaYNovel strategies for microdose studies using non-radiolabeled compoundsAdv Drug Deliv Rev2011637 532 53821345359
- LappinGNoveckRBurtTMicrodosing and drug development: past, present and futureExpert Opin Drug Metab Toxicol201397 817 83423550938
- BurtTYoshidaKLappinGMicrodosing and other phase 0 clinical trials: facilitating translation in drug developmentClin Transl Sci201692 74 8826918865
- US Food and Drug AdministrationGuidance for industry, investigators, and reviewers: exploratory IND studies2006 Available from: www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm078933.pdfAccessed March 16, 2017
- FujitaKYoshinoEKawaraKA clinical pharmacokinetic micro-dosing study of docetaxel with Japanese patients with cancerCancer Chemother Pharmacol2015764 793 80126297058
- CroftMKeelyBMorrisITannLLappinGPredicting drug candidate victims of drug-drug interactions, using microdosingClin Pharmacokinet2012514 237 24622335429
- HalamaBHohmannNBurhenneJWeissJMikusGHaefeliWEA nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactionsClin Pharmacol Ther2013936 564 57123511711
- KangBCYangCQChoHKSuhOKShinWGInfluence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteersBiopharm Drug Dispos2002232 77 8111932962
- IeiriIKubotaTUraeAPharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjectsClin Pharmacol Ther1996596 647 6538681489
- Prilosec (omeprazole) [package insert]LondonAstraZeneca2012
- RidtitidWWongnawaMMahatthanatrakulWPunyoJSunbhanichMRifampin markedly decreases plasma concentrations of praziquantel in healthy volunteersClin Pharmacol Ther2002725 505 51312426514
- No authors listedGuidance for industry, investigators, and reviewers: exploratory IND studiesBiotechnol Law Rep2006252 167 174
- FrerichsVAZaranekCHaasCEAnalysis of omeprazole, midazolam and hydroxy-metabolites in plasma using liquid chromatography coupled to tandem mass spectrometryJ Chromatogr B Analyt Technol Biomed Life Sci20058241 71 80
- VittalSGanneboinaRLayekBHighly sensitive method for the determination of omeprazole in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a clinical pharmacokinetic studyBiomed Chromatogr2009234 390 39618937302
- NarasimhanNIDorerDJDavisJTurnerCDSonnichsenDEvaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjectsClin Pharmacol Drug De201545 354 360
- Hassan-AlinMAnderssonTNiaziMRöhssKA pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjectsEur J Clin Pharmacol20056011 779 78415578172
- WuFGaohuaLZhaoPPredicting nonlinear pharmacokinetics of omeprazole enantiomers and racemic drug using physiologically based pharmacokinetic modeling and simulation: application to predict drug/genetic interactionsPharm Res2014318 1919 192924590877
- FurutaTShiraiNSugimotoMNakamuraAHishidaAIshizakiTInfluence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapiesDrug Metab Pharmacokinet2005203 153 16715988117